Efficacy and Safety of Dulaglutide Biosimilar LY05008 Versus the Reference Product Dulaglutide (Trulicity) in Chinese Adults With Type 2 Diabetes Mellitus: A Randomized, Open-Label, Active Comparator Study.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- Efficacy and Safety of Dulaglutide Biosimilar LY05008 Versus the Reference Product Dulaglutide (Trulicity) in Chinese Adults With Type 2 Diabetes Mellitus: A Randomized, Open-Label, Active Comparator Study.
- Published In:
- Journal of diabetes, 17(4), e70077 (2025)
- Authors:
- Liu, Li(2), Cheng, Zhifeng(5), Wang, Lianwei, Zhang, Lili, Li, Shunbin, Li, Shu, Pang, Shuguang, Li, Qifu, Bian, Fang, Gu, Junling, Shen, Jie, Fu, Liujun, Sun, Baiping, Zhao, Yanyan, Dou, Changlin, Zeng, Zhaoyang, Guo, Lixin
- Database ID:
- RPEP-12221
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-12221APA
Liu, Li; Cheng, Zhifeng; Wang, Lianwei; Zhang, Lili; Li, Shunbin; Li, Shu; Pang, Shuguang; Li, Qifu; Bian, Fang; Gu, Junling; Shen, Jie; Fu, Liujun; Sun, Baiping; Zhao, Yanyan; Dou, Changlin; Zeng, Zhaoyang; Guo, Lixin. (2025). Efficacy and Safety of Dulaglutide Biosimilar LY05008 Versus the Reference Product Dulaglutide (Trulicity) in Chinese Adults With Type 2 Diabetes Mellitus: A Randomized, Open-Label, Active Comparator Study.. Journal of diabetes, 17(4), e70077. https://doi.org/10.1111/1753-0407.70077
MLA
Liu, Li, et al. "Efficacy and Safety of Dulaglutide Biosimilar LY05008 Versus the Reference Product Dulaglutide (Trulicity) in Chinese Adults With Type 2 Diabetes Mellitus: A Randomized, Open-Label, Active Comparator Study.." Journal of diabetes, 2025. https://doi.org/10.1111/1753-0407.70077
RethinkPeptides
RethinkPeptides Research Database. "Efficacy and Safety of Dulaglutide Biosimilar LY05008 Versus..." RPEP-12221. Retrieved from https://rethinkpeptides.com/research/liu-2025-efficacy-and-safety-of
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.